NRIX Company Profile and Key Details
Nurix Therapeutics, Inc.
NRIX Stock Price Chart
Stock Price Today
Nurix Therapeutics, Inc. (NRIX) stock surged +0.15%, trading at $19.71 on NASDAQ, up from the previous close of $19.68. The stock opened at $19.49, fluctuating between $19.38 and $19.99 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Company Information
| Employees | 284 |
| Beta | 2.2 |
| Sales or Revenue | $76.99M |
| 5Y Sales Change% | -0.391% |
| Fiscal Year Ends | November |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Nurix Therapeutics, Inc. (NASDAQ: NRIX) stock price is $19.71 in the last trading session. During the trading session, NRIX stock reached the peak price of $19.99 while $19.38 was the lowest point it dropped to. The percentage change in NRIX stock occurred in the recent session was 0.15% while the dollar amount for the price change in NRIX stock was $0.03.
The NASDAQ listed NRIX is part of Biotechnology industry that operates in the broader Healthcare sector. Nurix Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Howard A. Simon J.D., Esq., SPHR
Vice President of Operations & Corporation Counsel
Dr. Christine Ring
Gen. Counsel & Sec.
Rita Kwong
Senior Accounting Mang.
Mr. Howard A. Simon Esq., J.D., SPHR
Vice President of Operations & Corporation Counsel
Ms. Stefani A. Wolff
Chief Operating Officer & Executive Vice President of Product Devel.
Dr. Gwenn M. Hansen Ph.D.
Chief Scientific Officer
Dr. Arthur T. Sands M.D., Ph.D.
Chief Executive Officer, Pres & Director
Mr. Johannes Van Houte
Chief Financial Officer
Dr. John Kuriyan Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Michael Rapé Ph.D.
Founder & Member of Scientific Advisory Board
Prof. Arthur Weiss M.D., Ph.D.
Founder & Member of Scientific Advisory Board
Mr. Eric C. Schlezinger J.D.
Chief People Officer
Dr. Arthur Weiss M.D., Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Michael T. Lotze F.A.C.S., M.D.
Chief Cellular Therapy Officer
Dr. Christine Ring J.D., Ph.D.
Gen. Counsel & Sec.
Dr. Jason Kantor Ph.D.
Executive Vice President of Fin. & Bus. Strategy
NRIX's closing price is 157.25% higher than its 52-week low of $7.65 where as its distance from 52-week high of $29.56 is -33.42%.
Number of NRIX employees currently stands at 284.
Official Website of NRIX is: https://www.nurixtx.com
NRIX could be contacted at phone 415 660 5320 and can also be accessed through its website. NRIX operates from 1700 Owens Street, San Francisco, CA 94158, United States.
NRIX stock volume for the day was 180.64K shares. The average number of NRIX shares traded daily for last 3 months was 905.51K.
The market value of NRIX currently stands at $1.40B with its latest stock price at $19.71 and 70.84M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com